

## State of Oklahoma SoonerCare

## Sarclisa® (Isatuximab-irfc) Prior Authorization Form

Member Name:	Date of Birth:	: Member ID#:	
Drug Information			
☐ Physician billing (HCPCS code	e:) 🗖	Pharmacy billing (NDC:	
Start Date (or date of next dose):	Dose:	Regimen:	
	Billing Provider	Information	
Provider NPI:	Provider	Name:	
Provider Phone:	Provider Fax:		
Prescriber Information			
Prescriber NPI:	Prescriber Na	ame:	
Prescriber Phone:	Prescriber Fax:	Specialty:	
	Criteri	a	
<ul> <li>a. If yes, has the member faint.</li> <li>i. If yes, did the prior the Yes No</li> <li>3. Will isatuximab be used in cornal.</li> <li>4. If diagnosis is NOT relapsed of the prior the Yes, has the member faint.</li> </ul>	iled at least 2 prior the erapies include lenalide mbination with carfilzor iled 1 to 3 prior therapion refractory multiple m	omide and a proteasome inhibitor? mib and dexamethasone? Yes No	
	adverse drug reaction		
I certify that the indicated treatme	<b>nt is medically necess</b> not send in chart notes	ary and all information is true and correct to the s. Specific information will be requested if	

## PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 147 1/6/2022